Central antitussive effect of codeine in the anesthetized rabbit

Abstract

Background

Codeine represents a commonly used drug to suppress cough. Central antitussive effect of codeine has been confirmed in a number of animal studies. However, available data related to antitussive activity of codeine in rabbits are very limited.

Objective

We investigated the effects of codeine on cough, single expiratory responses (expiration-like reflex) induced by mechanical tracheo-bronchial stimulation, and on the sneeze reflex in the anesthetized rabbit.

Materials and methods

Twenty pentobarbitone anesthetized spontaneously breathing rabbits were used for the study. Increasing doses of codeine (codeinum dihydrogenphosphate, Interpharm) were injected intravenously (iv); 0, 0.15, 0.76, and 3.78 mg/kg of codeine dissolved in saline, 0.25 ml/kg) or intracerebroventricularly (icv); 0, 0.015, 0.076, and 0.378 mg/kg of codeine dissolved in artificial cerebrospinal fluid, 0.033 ml/kg.

Results

Both iv and icv injections of codeine led to a dose-dependent reduction of coughing provoked by tracheo-bronchial stimulation; however, the doses differed substantially. The effective cumulative dose for a 50% reduction in the number of coughs was 3.9 and 0.11 mg/kg after iv and icv administration of codeine, respectively; representing about 35-fold higher efficacy of the icv route. The numbers of expiration-like responses and sneeze reflex responses remained unchanged.

Conclusions

The study confirmed the central antitussive effect of codeine, but showed a low sensitivity of sneeze and expiration reflex to codeine. We validated the experimental model of an anesthetized rabbit for studies on central antitussive action.

Introduction

Antitussive drugs, such as codeine and dextromethorphan, are among the most commonly prescribed medicines in the world. Codeine acts antitussively within the brain stem, where the basic neuronal circuitry responsible for coughing is located [1–3]. Central action of codeine is accepted, since the drug is more effective when administered centrally, either via the vertebral artery or intracerebroventricularly (icv) into the 4^th brain ventricle, compared with an intravenous (iv) route [4].

Codeine is considered to be primarily the μ-opioid receptor agonist [5, 6]. However, for central antitussives, including codeine, also other than μ-opioid receptor mechanisms have been proposed [5, 7–9].

Codeine reduces the number of coughs provoked by tracheo-bronchial stimulation; decreasing the expiratory (E) component of cough efforts, with a much lower effect on the inspiratory (I) one, cough timing, and parameters of respiration [10, 11]. However, a complete analysis of the effect of codeine on cough motor pattern has never been performed in the rabbit [12].

Previous studies have shown the effective antitussive dose of codeine in experimentally produced cough in anesthetized rabbits was 100 mg/kg for oral and 1-10 mg/kg for iv administration [13, 14]. However, none of the studies have attempted to analyze and determine ED₅₀ (effective dose for 50% reduction of coughing) providing the base for comparison of antitussive efficacy upon different routes of codeine administration and for the determination of its central or peripheral action [4, 11].

In the present study we investigated the hypothesis that in the rabbit the codeine would centrally suppress tracheo-bronchial cough at a lower dose than that required for iv administration.

Materials and methods

General Procedures and Stimulation

All procedures were performed in accordance with the laws, rules, and regulations of Slovakian Government and EC; the Ethics Committee of Jessenius Faculty of Medicine in Martin approved the protocols.

Experiments were performed in 20 rabbits (New Zeland white, line P91; 3.65 ± 0.15 kg) of either sex, pre-medicated with the diazepam (Apaurin, KRKA, Croatia; 5 mg/kg, im) and anesthetized with sodium pentobarbital (Biowet, Pulawy, Poland; 35 mg/kg, ip). Supplementary anesthetic doses were administered (13 mg/kg, iv) as needed. Atropine (Biotika; 0.15 mg/kg, iv) was given at the beginning of the experiment to reduce secretions. The trachea, femoral artery and vein were canulated. The animals were allowed to breathe spontaneously a gas mixture of 30-60% oxygen, balanced by nitrogen. Arterial blood pressure (BP), end-tidal CO₂ concentration (ETCO₂), respiratory rate (RR), and body temperature were monitored continuously. Body temperature was maintained at 39.0 ± 0.5°C. Periodically, the samples of arterial blood were removed for blood gases and pH analysis.

Bipolar fine wire hook electrodes were placed in the crural diaphragm (DIA) and bilaterally in the transversal abdominal, or the external oblique abdominal muscles (ABD) for electromyogram (EMG) recordings. A soft balloon was inserted into the esophagus for a measurement of the intrathoracic pressure changes (esophageal pressure - EP). Foramen magnum with the occipital bone was carefully exposed, a thin polyethylene catheter was inserted throughout and fixed in dura mater for central injections of codeine. The tip of the catheter was positioned about 2 mm rostral to the obex (the most caudal point of the area postrema) in the 4^th brain ventricle. The position and patency of the catheter were tested post-mortem.

Tracheo-bronchial cough was induced by a mechanical stimulation of the trachea and the carina areas with a nylon loop attached to a soft catheter. This tool was inserted into the trachea and moved fore and back toward carina 4 times during one stimulation trial. Sneeze was induced by mechanical stimulation (4 touches) of the nasal septum with a soft nylon fiber (Ø 0.3 mm). Cough or sneeze were defined by a large augmenting burst of diaphragm (DIA) EMG activity immediately followed (and partially overlapped) by a burst of E abdominal (ABD) EMG activity corresponding to the related I-E wave of EP. Stimulation of tracheo-bronchial airways also resulted in single expiratory responses (ER-like response) independent of, and separated from, the previous inspiration. These expiratory responses were analyzed separately from coughing.

Codeinum dihydrogenphosphate (Interpharm, Bratislava, Slovakia) was dissolved in saline for iv (via femoral vein; 0.25 ml of solution/kg) and in the artificial cerebrospinal fluid (aCSF) for icv injection (via the catheter fixed in the foramen magnum; 0.033 ml of so-lution/kg). Increasing doses of codeine were injected iv (pure saline followed by 0.2, 0.8, and 4.0 mg/kg), representing cumulative doses of 0, 0.15, 0.76, and 3.78 mg/kg or icv (pure aCSF followed by 0.02, 0.08, and 0.4 mg/kg), representing cumulative doses of 0, 0.015, 0.076, and 0.378 mg/kg of codeine). Stimulation of tracheo-bronchial airways and the nasal mucosa were performed at 1 min intervals; two stimulation trials before the first (saline or aCSF) and after each injection. During the icv injection protocol, additional stimulations were performed more than 30 min after the last injection ('recovery'). The experiment was terminated by an iv overdose of pentobarbitone, followed by a saturated solution of KCl.

Data Processing and their Analysis

All EMGs were amplified, filtered (300-3000 Hz; Iso DAM8, WPI), digitalized (12-bit multi-function plug-in ISA card, Dataq Instruments, OH, USA, sampling frequency of 20.000 Hz), and recorded (WinDaq, Dataq Instruments - Akron, OH, USA) along with the waveforms of BP and EP.

The number of cough efforts and single expiratory responses induced during the mechanical probing of the lower airways (mean number of coughs and single expiratory efforts - EN per 4 penetrations and touches of carina) and the number of sneeze efforts in response to stimulation of the nasal septum (mean number of sneezes - SN per 4 touches of nasal mucosa) were analyzed in each sequence of trials. We also performed a complex spatiotemporal analysis of studied responses (cough, sneeze, single expiratory responses) including the duration of DIA, ABD activity, augmenting and decrementing part of these activities, overlapping of them, the duration of quiescent period between coughs or sneezes (the intervals from the end of ABD activity to the beginning of the next DIA activity such as next cough/sneeze or eupneic inspiration). Differences in amplitudes of DIA and ABD moving averages and of I and E components of the esophageal pressure recording between those obtained in response to saline or aCSF and codeine injections were measured.

The results are expressed as means ± SE. For statistical analysis t-test, Mann-Whitney U test, and repeated measures ANOVA with the Student-Newman-Keuls post-hoc test were applied as appropriate. The differences of variables were considered significant at P < 0.05.

Results

Mechanical tracheal-bronchial stimulation produced coughing and single expiratory responses (Figure 1), while nasal stimuli resulted in vigorous sneezing in our animals (Figure 2). Spatiotemporal analysis of the cough reflex during sequential stimulation (up to 6 stimulation sequences, each with 2 tracheo-bronchial stimulation trials) showed no significant differences. No significant differences were also detected in the parameters of induced responses before and after injection (saline for iv and aCSF for icv protocols).

Figure 1

Increasing doses of codeine injected icv (0.4 mg/kg) reduced the tracheobronchial coughing. BP - blood pressure; EP - esophageal pressure; DIA - integrated EMG of the diaphragm; ABD - integrated EMG of abdominal muscles; Stim - tracheobronchial stimulation.

Figure 2

Increasing doses of codeine injected icv (0.4 mg/kg) did not affect sneezing. BP - blood pressure; EP - esophageal pressure; DIA - integrated EMG of the diaphragm; ABD - integrated EMG of abdominal muscles; Stim - nasal stimulation.

Increasing doses of codeine, injected either iv or icv, reduced the number of coughs, the cough expiratory effort expressed in the esophageal pressure recording, and ABD EMG moving average amplitudes (Table 1). The number of coughs and the difference in cough ABD EMG amplitude following the highest dose of codeine, in both icv and iv protocols, were significantly lower than those at the 5^th sequence of repetitive control cough stimulations (Table 1). A reduced number of coughs was associated with a tendency for a prolongation of the period of relative motor quiescence during the cough expiratory period (in case of repetitive coughing representing the inter-cough interval within the cough trial) and of the total cough cycle duration. We found no differences in the expression of EN or SN, their intensities, or timing of single expiratory responses and sneezes during both icv and iv codeine protocols.

Table 1 Parameters of coughing after iv and icv application of increasing doses of codeinum dihydrogenphosphate (mg/kg).

Furthermore, we found a linear relationship between cough number reduction and the logarithm of the cumulative codeine dose (r = 0.95 and r = 0.98 for iv and icv protocols, respectively), with the slopes significantly different from zero (P < 0.05). The effective doses of codeine for 50% reduction in the cough number (ED₅₀), extrapolated from the regression analysis, were 3.9 and 0.11 mg/kg for iv and icv administration. The ivED₅₀/icvED₅₀ ratio was ~35. We found no appreciable differences in RR and BP during our protocols, with the exception of a slightly reduced mean BP (from 10.5 ± 1.0 to 9.5 ± 1, 0; P < 0.01) following the highest iv codeine dose.

Discussion

The major finding of this study was that codeine suppressed the cough reflex in the anesthetized rabbit, and that intracerebroventricular route of its administration was much more efficient to this end. Thus, the results confirmed the central antitussive effect of codeine in response to mechanically-induced tracheobronchial cough. In contrast, sensitivity of the sneeze and expiration-like reflexes to codeine was low. In addition, we validated the experimental model of an anesthetized rabbit for studies on central antitussives.

In this study we performed sequential tracheobronchial stimulation for up to 13 times and demonstrated a stable cough response during these control, non-injection trials. The stability of coughing allowed us to compare coughing in codeine-treated and -untreated animals. The number of coughs and E efforts during coughing was reduced in codeine-treated rabbits (at the highest dose of codeine) compared with the 5^th series (5^th pair) of stimulations in the untreated rabbits, and also when compared with coughing after the vehicle injection alone in codeine-treated animals. We further showed that the dose of codeine necessary for a 50% reduction in the number of coughs (ED₅₀) was many-fold smaller in case of icv than iv codeine administration. That points to a central site of antitussive action of codeine in the anesthetized rabbit as it has also been reported by others [11, 15]. Our results showing suppression of cough by codeine and the analysis of temporary cough characteristics that is similar to previous data in cats [12] support the notion that central antitussive drugs act by the inhibition of specific components of the cough neuronal control and do not generally suppress all aspects of its motor task [10, 11].

Codeine is a μ-opioid receptor agonist. These receptors are abundantly expressed in the brainstem areas involved in cough production, such as the ambiguus, solitary tract, medial parabrachial, and raphe nuclei, and possibly the periaqueductal gray matter [5]. However, the antitussive effects of different μ-opioid receptor agonists greatly vary, as also does the efficacy of codeine in cough suppression in individual animal species [16]. The antitussive effects of codeine are only little blocked by naloxone, a non-specific opioid receptor antagonist, mainly in cats [5].

Thus, the exact structures and neuronal populations that are affected by central antitussives to reduce cough are largely unknown. Application of different antitussive agents (DAMGO and baclofen) within the caudal aspect of the solitary tract nucleus in the rabbit induces decreases in the number of coughs, peak abdominal activity, and in the duration of the cough respiratory cycle; the latter being augmented due to cough-related prolongation of both I and E components of the cycle. In the present study we found no significant changes in the total cough cycle duration or I and E cough phase durations during our codeine protocols. Those findings are in line with the lack of changes in temporal characteristics of cough being reported after codeine microinjections into the caudal part of the ventral respiratory group in cats [12]. This study also confirmed the lack of a suppressive effect of codeine on sneeze and 'expiration-like' single reflex expiratory responses after codeine, which accords with other studies [15, 17] and indicates different central control mechanisms for cough and the other two reflex responses.

A limitation of this and other studies is a mechanical probing in the tracheo-bronchial region to induce cough. Pathological cough seems to be more related to chemical stimuli, involving peripheral and central plasticity and up-regulation of cough at multiple levels of the cough neural pathway [10, 11, 18]. Cough is a complex phenomenon affected by a number of systemic and regulatory malfunctions, and non-specific environmental factors [18–20].

In this study we did not detect changes in respiratory rate or blood pressure after the application of increasing doses of codeine. That indicates a limited respiratory effect of central antitussives at a dose which is capable of suppressing the cough reflex, which has also been found in other reports [11]. However, we detected a weak, but statistically significant, decrease in BP after iv application of the highest dose of codeine. Other authors have previously shown that codeine causes a combination of pulmonary vasoconstriction and systemic vasodilation in the anesthetized dog [21], and opioids, in higher doses, generally reduce peripheral and aortic systolic, mean, and end-systolic pressures [22]. In clinical use of codeine as an antitussive agent these possible untoward effects should thus be taken into consideration.

Conflicts of interests

The authors declare that they have no competing interests.